Comparative Pharmacology
Head-to-head clinical analysis: FERRLECIT versus TRILITRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRLECIT versus TRILITRON.
FERRLECIT vs TRILITRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric carboxymaltose, a polynuclear iron(III)-hydroxide carbohydrate complex, provides a source of iron for hemoglobin synthesis and erythropoiesis. The iron is released to endogenous iron transport proteins, such as transferrin, and stored as ferritin or hemosiderin.
TRILITRON is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
125 mg elemental iron (5 mL) intravenously over 1-5 minutes or as infusion over 15-30 minutes, repeated as needed based on iron deficiency.
10 mg orally once daily, with or without food.
None Documented
None Documented
Sodium ferric gluconate has a terminal half-life of approximately 1 hour for the intact complex. However, after dissociation, iron is rapidly cleared from plasma with a half-life of about 6 hours. The clinical context: the short half-life minimizes free iron toxicity but requires frequent dosing for iron replacement.
Terminal elimination half-life is 12-15 hours, allowing twice-daily dosing. Steady-state reached in 2-3 days.
Iron is not excreted renally; elimination is primarily through fecal loss of unabsorbed iron (approximately 80-90% of orally administered iron) and minor desquamation of mucosal cells. After IV administration, iron is incorporated into hemoglobin and storage pools; minimal urinary excretion (<1%). Biliary excretion of iron is negligible.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (15-20%). Biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Iron Replacement
Iron Replacement